HCM
ALXN

Highlander Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Highlander Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-500
Closed -$54K – 663
2019
Q4 		$54K Buy
500
+200
+67% +$21.4K 0.03% 289
2019
Q3 		$29K Hold
300
– – 0.02% 376
2019
Q2 		$39K Buy
+300
New +$38.7K 0.02% 353
2018
Q4 		– Sell
-300
Closed -$42K – 742
2018
Q3 		$42K Buy
+300
New +$37.6K 0.02% 373

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Highlander Capital Management's ALXN Position: Q1 2020 in Review

Highlander Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 500 shares — an estimated $54K sold.

Highlander Capital Management first reported a position in ALXN in Q3 2018 and held it in 4 quarters. The position peaked at $54K in Q4 2019. 653 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

  • Highlander Capital Management reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Highlander Capital Management sold 500 Alexion Pharmaceuticals shares in Q1 2020, an estimated $54K.
  • Highlander Capital Management first reported a position in Alexion Pharmaceuticals in Q3 2018 and held it in 4 quarters.
  • Highlander Capital Management's Alexion Pharmaceuticals position peaked at $54K in Q4 2019.
  • 653 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Highlander Capital Management's 13F filing for Q1 2020, filed 27 May 2020.